Scilex Holding Company

NASDAQ:SCLX

Drug Manufacturers - General

Healthcare
$6.34 -2.38%

-$0.17 today

Market cap
$53.83M
Beta
1.71
P/E (TTM)
-0.1
EPS (TTM)
-$60.90
52W Low $2.62High $21.34

Volume 0.00M

Average 0.13M

SCLX Inventory

Raw materials, work in progress, and finished goods held for sale.

Scilex Holding CompanyNASDAQ: SCLX

Inventory · Q1 FY2026 · quarter ended Mar 2026

Inventory rises 50.2% from a year ago

Inventory stood at $4.53M at the end of Q1 FY2026, up 50.2% from a year earlier and down 5.4% from the prior quarter. Over 3 fiscal years it compounded at +51.5% a year.

Context

  • Inventory amounted to 1.5% of total assets at the end of Q1 FY2026, down 2.3 pp from a year earlier.
  • Inventory increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether inventory keeps rising in the next quarterly balance sheet after a +50.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.53M-5.4% QoQ
Last fiscal yearDec 2025
$4.79M+96.6% YoY
Year agoMar 2025
$3.02M+50.2% since
Inventory past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+50.2%——
1 year+96.6%——
3-year CAGR+51.5%——
5-year CAGR——
10-year CAGR——

Inventory history

USD · from the balance sheet

Latest · FY2025
4.79M USD
Year-over-year change
+96.6%
4-year CAGR
+16.9%

Inventory vs competitors

How SCLX compares with its peers on the latest reported figures

  • SCLX's Mar 2026 inventory of $4.53M is the 3rd highest of the 9 companies compared; the peer median is $0.
  • Its year-over-year change of +50.2% is the 2nd highest of 4, against a peer median of +47.7%.
  • Inventory amounts to 1.5% of total assets for SCLX, versus a peer median of 0.0%.
SCLX Competitors Peer median
Inventory for SCLX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CTORCitius Oncology, Inc.Mar 2026$22.66M +47.7%—22.5%
SEERSeer, Inc.Mar 2026$8.08M +14.3%+19.0%3.0%
SCLXScilex Holding CompanyMar 2026$4.53M +50.2%+51.5%1.5%
LUCDLucid Diagnostics Inc.Mar 2026$1M +106.8%+47.1%2.9%
IRDOpus Genetics, Inc.Mar 2026$0 ——0.0%
AGENAgenus Inc.Mar 2026$0 ——0.0%
ALECAlector, Inc.Mar 2026$0 ——0.0%
ABOSAcumen Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
INOInovio Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
Peer median (excluding SCLX) $0+47.7%+33.0%0.0%

Competitors are the stored peer set for SCLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents4.34M2.18M3.92M3.27M4.96M
Short-term Investments00006.03M
Net Receivables14.27M21.24M34.6M26.44M15.24M
Inventory2.56M1.38M4.21M2.44M4.79M
Other Current Assets1.83M009.4M7.34M
Total Current Assets23M29.61M46.78M41.55M38.36M
Property, Plant & Equipment (Net)2.11M1.9M3.67M2.93M28.42M
Goodwill13.48M13.48M13.48M13.48M13.48M
Intangible Assets38.8M40.59M36.49M32.45M59.09M
Long-term Investments00808K2.42M1M
Tax Assets00000
Other Non-current Assets538K944K89K119K224.64M
Total Non-current Assets54.93M56.92M54.53M51.41M326.62M
Total Assets77.93M86.53M101.31M92.95M364.98M
Account Payables4.28M8.45M40.95M52.62M86.27M
Short-term Debt57.56M0108.43M34.88M92.28M
Tax Payables001.45M876K0
Deferred Revenue00000
Other Current Liabilities0264K491K169.04M301.79M
Total Current Liabilities169.42M44.84M250.38M259.64M483.65M
Long-term Debt95.54M017.04M845K27.12M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)5.19M002.69M0
Other Non-current Liabilities30.51M4.78M4.59M20.91M52.81M
Total Non-current Liabilities132.39M5.45M23.87M25.96M93.08M
Total Liabilities301.81M50.29M274.25M285.59M576.73M
Common Stock13K14K16K24K1K
Retained Earnings(352.55M)(375.91M)(490.25M)(563.05M)(921.79M)
Accumulated OCI0(0)06.32M(5.8M)
Other Stockholders Equity00000
Minority Interest0000(3.97M)
Total Equity(223.88M)36.24M(172.94M)(192.64M)(211.75M)
Total Debt154.75M1.41M128.46M37.96M132.54M
Net Debt150.41M(774K)124.54M34.69M127.59M

Scilex Holding Company

NASDAQ:SCLX

Intrinsic Alpha fair value

Locked

Current Price

$6.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.